Impact of the Inclusion of an Aminoglycoside to the Initial Empirical Antibiotic Therapy for Gram-Negative Bloodstream Infections in Hematological Neutropenic Patients: a Propensity-Matched Cohort Study (AMINOLACTAM Study) | Zendy

Adaia AlbasanzPuig | Zendy; Carlota Gudiol | Zendy; Pedro PuertaAlcalde | Zendy; Çağlayan Merve Ayaz | Zendy; Marina Machado | Zendy; Fabián Herrera | Zendy; Pilar MartínDávila | Zendy; Júlia Laporte-Amargós | Zendy; Celia Cardozo | Zendy; Murat Akova | Zendy; Ana ÁlvarezUría | Zendy; Diego Torres | Zendy; Jesús Fortün | Zendy; Carolina GarcíaVidal | Zendy; Patricia Muñóz | Zendy; Alba Bergas | Zendy; Helena Pomares | Zendy; Santiago Mercadal | Zendy; Xavier Durà-Miralles | Zendy; Esther García-Lerma | Zendy; Natàlia Pallarès | Zendy; Jordi Carratalà | Zendy

Open Access

Impact of the Inclusion of an Aminoglycoside to the Initial Empirical Antibiotic Therapy for Gram-Negative Bloodstream Infections in Hematological Neutropenic Patients: a Propensity-Matched Cohort Study (AMINOLACTAM Study)

Author(s) -

Adaia AlbasanzPuig,

Carlota Gudiol,

Pedro PuertaAlcalde,

Çağlayan Merve Ayaz,

Marina Machado,

Fabián Herrera,

Pilar MartínDávila,

Júlia Laporte-Amargós,

Celia Cardozo,

Murat Akova,

Ana ÁlvarezUría,

Diego Torres,

Jesús Fortün,

Carolina GarcíaVidal,

Patricia Muñóz,

Alba Bergas,

Helena Pomares,

Santiago Mercadal,

Xavier Durà-Miralles,

Esther García-Lerma,

Natàlia Pallarès,

Jordi Carratalà

Publication year - 2021

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00045-21

Subject(s) - medicine , propensity score matching , cefepime , case fatality rate , odds ratio , neutropenia , amikacin , combination therapy , antibiotics , retrospective cohort study , gastroenterology , microbiology and biotechnology , antibiotic resistance , epidemiology , chemotherapy , imipenem , biology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research